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Abstract
Background: Breast cancer (BC) detection in women with a genetic susceptibility or strong family history is
considered mandatory compared with BC screening in the general population. However, screening modalities
depend on the level of risk. Here we present an update of our screening programs based on risk classification.
Methods: We defined different risk categories and surveillance strategies to identify early BC in 1325 healthy
women recruited by the Modena Study Group for familial breast and ovarian cancer. Four BC risk categories
included BRCA1/2 carriers, increased, intermediate, and slightly increased risk. Women who developed BC from
January 1, 1994, through December 31, 2005 (N = 44) were compared with the number of expected cases
matched for age and period. BRCA1/2 carriers were identified by mutational analysis. Other risk groups were
defined by different levels of family history for breast or ovarian cancer (OC). The standardized incidence ratio
(SIR) was used to evaluate the observed and expected ratio among groups. All statistical tests were two-sided.
Results: After a median follow-up of 55 months, there was a statistically significant difference between observed
and expected incidence [SIR = 4.9; 95% confidence interval (CI) = 1.6 to 7.6; p < 0.001]. The incidence observed
among BRCA carriers (SIR = 20.3; 95% CI = 3.1 to 83.9; P < 0.001), women at increased (SIR = 4.5; 95% CI = 1.5
to 8.3; P < 0.001) or intermediate risk (SIR = 7.0, 95% CI = 2.0 to 17.1; P = 0.0018) was higher than expected,
while the difference between observed and expected among women at slightly increased risk was not statistically
significant (SIR = 2.4, 95% CI = 0.9 to 8.3; P = .74).
Conclusion: The rate of cancers detected in women at high risk according to BRCA status or strong family
history, as defined according to our operational criteria, was significantly higher than expected in an age-matched
general population. However, we failed to identify a greater incidence of BC in the slightly increased risk group.
These results support the effectiveness of the proposed program to identify and monitor individuals at high risk,
whereas prospective trials are needed for women belonging to families with sporadic BC or OC.
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Background
Following the discovery the mutant BRCA1 and BRCA2
genes which predispose carriers for BC and OC [1,2],
many high-risk women request genetic testing and coun-
selling on strategies to reduce their risk of death from BC.
There are several options available for the management
and care of women at risk for developing BC. Primary pre-
vention can be achieved by prophylactic mastectomy and/
or other risk-reducing strategies, e.g. chemoprevention
with Tamoxifen, or oophorectomy. Prophylactic mastec-
tomy is usually not proposed as the first choice for the
management of women at high risk for developing BC,
although it has been demonstrated to be efficient in
reducing the incidence of BC either in women belonging
to families with familial [3] or hereditary BC [4,5]. Other-
wise, secondary prevention through intensified surveil-
lance to identify the earliest possible diagnosis of familial
BC at a prognostically favourable stage is considered a fea-
sible and acceptable strategy. If intensified surveillance is
chosen, we have to keep in mind that there is difference
between women with a positive genetic test who face a
lifetime risk of 46–87% [6,7] and women with a calcu-
lated lifetime risk of ≥ 18%, according to specific models,
e.g. Claus [8,9]or Gail [10]. Depending on BRCA status or
family history, management of women at increased risk
for developing breast cancer has to be considered as an
individual surveillance program. The most widely recom-
mended strategy for BRCA carriers entails frequent,
intense surveillance that begins at age 25 to 35 years. How
to screen these patients is also debatable. There is no con-
sensus on the optimum modality and screening interval
of women identified to be at moderate or high risk of
breast cancer. [11,12]. We know that the "lead time" will
be short, in BRCA related BC, due to this forms rapid
growth rate, and the screening performed at shorter inter-
vals [13]. Furthermore, although mammography remains
the gold standard tecnique, the radiation risk, due to the
fact that BRCA genes are implicated in DNA repair of dou-
ble stranded breaks typically caused by ionizing radiation
[14,15], and the diminished sensitivity in dense breasts,
lead to evaluate the efficacy and safety of other imaging
screening modalities for breast cancer, such as ultrasound
and MRI. In particular, ultrasound has an established role
in complementing diagnostic mammography in young
patients with dense breasts [16-18]. Considering MRI, two
retrospective [19,20] and five prospective studies [21-25]
have suggested that this imaging technique is useful in
screening high risk women.
Several guidelines for hereditary breast cancer (HBC) and
familial BC have been published. Particularly, for familial
breast cancer, three groups of risk have been defined
(high, moderate and low), according to the number of
affected relatives, the age at onset and the cancers associ-
ated. All women belonging to moderate/high risk should
be offered annual mammography, but MRI and ultra-
sound should not be used in routine surveillance [26,27].
With the objective of improving the impact of different BC
screening strategies in women in different risk categories,
we developed operational criteria for the selection of fam-
ily groups at risk of developing BC. Four categories were
defined and four different BC screening strategies were
established, in terms of age to begin screening, screening
intervals, and imaging techniques. Here we describe the
results of our surveillance and document the effectiveness
of the proposed program in selecting individuals at risk.
Methods
Study population
Beginning in 1994, 1628 family histories were collected
by the Modena Study Group for Familial Breast and Ovar-
ian Cancer, in accordance with an oncologist-based
model of cancer genetic counselling for HBC and heredi-
tary OC (HOC) [28]. The family histories were obtained
through detailed questionnaires and interviews. Family
pedigrees were traced as far backward and laterally as pos-
sible, including a minimum of four generations and
extended to paternal lines. The BC risk estimate was
assessed according to the Gail model [10], Claus tables
[8,9] and a slightly modified BRCAPro model, adapted to
the Italian population as suggested by Marroni et al. [29].
Furthermore, risk estimation was also determined accord-
ing to the following criteria: 1) at least three relatives diag-
nosed with BC or OC in two different generations; 2) at
least one of the three relatives must be a first-degree rela-
tive of one of the other two; in the case of male interposi-
tion, a relationship of different degree is allowed; 3) at
least one BC must be diagnosed before the age of 40 years
or be bilateral; 4) at least one BC diagnosed at age ≤ 35,
regardless of family history; 5) at least one BC and one OC
in the same woman, regardless of family history; 6) at
least one male BC, regardless of family history; 7) one
sporadic BC or OC. Applying these criteria, subjects were
classified at high, intermediate, or slightly increased risk
as described in Table 1. We defined the lifetime risk cut-
off, calculated by the Gail model, at 30–50% in the high
risk group, 18–29% in the intermediate risk group, and 6–
18% in the slightly increased risk group. Finally, a group
defined by a genetic predisposition due to the presence of
the mutant BRCA genes was established to have a lifetime
50–85% risk of developing BC.
After disclosure of the BC risk to the consultants, they
were instructed to convey suggestions concerning surveil-
lance to relatives who were at an increased risk with
respect to the general population.
To date, 1325 asymptomatic women accepted to be
enrolled in our surveillance program, of which 1072 were
first degree, and 253 were second degree relatives; 48BMC Cancer 2006, 6:210 http://www.biomedcentral.com/1471-2407/6/210
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women belonged to carrier group (37 were BRCA1 muta-
tion carriers, and 11 BRCA2 mutation carriers), 674
belonged to the high risk group, 257 to the intermediate
risk group, and 346 to the slightly increased risk group
(Table 2).
Additionally, 299 healthy women belonging to collected
pedigrees did not adhere to our surveillance program for
the following reasons: a) consultants failed to communi-
cate the information to other relatives due to a poor rela-
tionship between family member; b) although they were
informed of belonging to an at-risk family, they decided
not to undergo surveillance due to low interest or because
they lived too far from the clinic.
Genetic testing
Genetic testing to identify deleterious BRCA1 and BRCA2
mutations included direct automated sequencing on the
entire coding sequence. From 1995 to 2005, 385 index
cases affected by BC or OC, in the high risk categories,
were tested for BRCA1/2 mutations of which, 82 carrier
patients (21.3%) were identified. Of these 82 carriers, 79
asymptomatic relatives were found to carry a BRCA muta-
tion.
Table 2: Patient characteristics
Risk group Life time risk of BC* (%) N° of women Mean age at surveillance Years 
(Range)
N° with 1st/2nddegree 
relatives
Carriers 50–80 48 42 (20–75) 40/8
High 30–50 674 42 (15–75) 500/174
Intermediate 18–30 257 43 (19–67) 229/28
Slightly increased 6–18 346 40 (18–75) 303/43
BC – breast cancer
*According to Gail model
Table 1: Modena model
High risk Pedigree classification
I) at least 3 relatives 
diagnosed with BC (or 
OC) in 2 different 
generations
II) one BC/OC case is a 
first-degree relative of the 
other 2 (of the other 1 if 
the first criterion is not 
fulfilled)°
III) at least one case has 
been diagnosed at the age 
≤ 40 or with bilateral BC
•••Hereditary HBC/*HBOC
•• Suspected Hereditary SHBC/SHBOC
•• Suspected Hereditary SHBC/SHBOC
BC diagnosed at age ≤ 35, regardless of family history Early Onset EOBC
BC and OC in the same woman, regardless of family history Breast Ovarian Cancer BOC
Intermediate risk
• Familial FBC/FBOC
••Strongly Suspected Familial **SFBC+ **SFBOC+
Male BC, regardless of family history Male Breast Cancer MBC
Slightly increased risk
• Suspected Familial **SFBC/**SFBOC
• Suspected Familial **SFBC/**SFBOC
BC/OC without any of the described criteria Sporadic Breast Cancer SpBC/SpOC
° male relatives excluded when calculating the degree of relationship
* If at least two of the malignancies are OC, the pedigree must be classified as HBOC even if the third criterion is not fulfilled.
**At least two cancer cases are required
HBC – hereditary breast cancer; HBOC -hereditary breast/ovarian cancer; SHBC-suspected hereditary breast cancer; SHBOC-suspected 
hereditary breast/ovarian cancer; EOBC-early onset breast cancer; BOC-breast ovarian cancer; FBC-familial breast cancer; FBOC-familial breast/
ovarian cancer; SFBC+- strongly suspected familial breast cancer; SFBOC+- strongly suspected familial breast/ovarian cancer; MBC-male breast 
cancer; SFBC- weakly suspected familial breast cancer; SFBOC- weakly suspected familial breast/ovarian cancer; SpBC- sporadic breast cancer; 
SpOC-sporadic ovarian cancerBMC Cancer 2006, 6:210 http://www.biomedcentral.com/1471-2407/6/210
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Surveillance
An open prospective nonrandomized study was designed
and approved by the Ethical Committee of Modena. Car-
riers of BRCA1 or BRCA2 mutations discovered through
genetic testing or subjects at risk according to our previ-
ously described criteria, who were at least 18 years of age
were eligible. Women with symptoms that were suggestive
of BC or women who had a personal history of BC were
excluded.
From January 1994 to September 2000, surveillance con-
sisted of mammography (oblique and craniocaudal views
and, if necessary, compression views and magnifications),
ultrasonography and clinical breast examination (CBE)
for BC prevention, and transvaginal ultrasound plus
Ca.125 serum levels for early diagnosis of OC were pro-
posed at different intervals based on the assessed risk. In
October 2000, surveillance for carriers of BRCA1 or
BRCA2 mutations was modified by introducing a
dynamic breast MRI with gadolinium-containing contrast
medium (Table 3). Whenever possible, the 4 independent
exams for each screening event were planned on the same
day during the second week of the menstrual cycle in pre-
menopausal women. When indicated, additional investi-
gation with fine-needle aspiration or core biopsy was
performed.
Data collection and statistics
All data regarding family and individual characteristics,
surveillance program, follow-up, additional investiga-
tions, and the final outcome of each examination from
the years 1992 to 2005 were collected in a database. A per-
son-year approach was used to evaluate the BC incidence.
Person-years of risk were calculated from the baseline visit
to the BC diagnosis (at surveillance or in the interval
between two examinations) or for those without diagno-
sis, to the end of the study period (December 31, 2005).
Detection rates were expressed as the number of events
per 1,000 person-years of follow-up, and confidence
intervals (CI) were calculated using the exact method [30].
Expected cancer incidence for consultants and for all first-
degree and second-degree relatives in the lineage at risk
older than 18 years was based on age-specific Modena
Cancer Registry (MCR) rates from 1998 through 2002 in
5-year age groups, beginning at age 25 years and ending
with age 85 years or older [31]. The observed women-
years at risk were then multiplied by expected cancer inci-
dence obtained from the MCR database to estimate the
total number of cancers expected. Standardized incidence
ratios (SIRs) were determined by calculating the ratio of
observed to expected numbers of cancers. An "interval
cancer" was defined as any cancer presenting between two
regular screening rounds. Interval cancer rate was defined
as the number of women with a diagnosis of an interval
cancer per 1,000 person-years at risk. Sensitivity of the
screening test was calculated as the ratio of BCs detected
by surveillance divided by the total number of BC (screen-
detected plus interval cancers). The chi-square test was
used to calculate P values. All statistical tests were two-
sided.
Results
Clinical characteristics
After a median follow-up of 55 months (range 1 to 151
months), a total of 44 breast tumors including 28 infiltrat-
ing (64%) and 16 ductal carcinomas in situ (DCIS) (36%)
were found in women belonging to different risk catego-
ries. Five cancers occurred in BRCA carriers (4 infiltrating
and 1 DCIS), 23 in the high risk group (14 infiltrating, 9
DCIS), 11 in the intermediate risk group (8 infiltrating
and 3 DCIS), and 5 in the slightly increased risk group (2
infiltrating and 3 DCIS). Among the 28 invasive tumors,
21 were ductal, 6 lobular, and one was a tubular carci-
noma. All patients were surgically treated. Of the 44
patients, 30 (68%) received conservative surgery, 14
(32%) had a mastectomy of which 6 were bilateral. At the
time of diagnosis, 17 patients were diagnosed with stage I
(63%), 7 with stage II, 2 with stage III, and 2 with stage IV.
Eight (29%) tumors were less then 10 mm in diameter, 10
(36%) were between 10 and 15 mm, 9 (32%) were greater
Table 3: Screening program for each risk category
Risk Categories Age at the 
beginning
Interval between 
CBE and US
Interval between 
mammography
Interval between 
MRI
Interval between 
transvaginal US and Ca.125 
serum levels
BRCA+ 25 6 months Annually Annually 6 months
High risk 30 6 months Every 2 years until age 
36, then annually
Annually
Intermediate risk 30 6 months 2 years until 40, then 
annually
Annually
Slightly increased risk 30 Annually One before 40 years, 
then every 18–24 
months
CBE – clinical breast exam; US – ultrasound; MRI – magnetic resonance imaging.BMC Cancer 2006, 6:210 http://www.biomedcentral.com/1471-2407/6/210
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than 15 mm (range 16 to 50 mm) and one was an inflam-
matory BC. Ten (36%) were node-positive. Five patients
were treated with hormonal therapy, 8 patients received
chemotherapy, 11 patients were treated with chemother-
apy and hormonal therapy, and 7 received surgery only. In
8 cases, chemotherapy was anthracycline-based. After a
median follow-up of 55 months, 4 recurrences and 3
deaths were observed, 2 for disease progression and one
due to heart failure. The actuarial 5 year survival rate was
93% (Fig. 1).
Efficacy of screening
With a total number of follow-up years of 6,066, the BC
detection rate (invasive and in situ BC) was 7.3 per 1000
person-years and 4.6 per 1000 person-years excluding
DCIS. Of the 44 patients who developed BC, 11 (25%)
were palpable and 33 (75%) were nonpalpable tumors.
Thirty-six of the 44 tumors were detected at screening (5
during the first round and 31 at a subsequent round) mak-
ing the rate of screen-detected cancers 5.9 per 1000. Eight
cancers, all identified by CBE, were diagnosed in the inter-
val between screening events (interval cancer rate 1.3 per
1000). The diagnosis was made only by CBE in 4 cases,
(one inflammatory carcinoma, 2 nipple bleeding, and
one axillary metastasis), by CBE plus ultrasonography in
3 cases, and by CBE plus ultrasound plus mammography
in one case. The time interval from the last negative screen
until diagnosis ranged from 1 to 14 months. The charac-
teristics of patients with interval cancers are shown in
Table 4.
Among the 36 screen-detected BC, 3 were palpable and 33
were nonpalpable cancers. Twenty-eight were diagnosed
with mammography (78%), 18 with ultrasound (50%),
35 with mammography plus ultrasound (97%), and 4 by
MRI (100%) (Table 5). An MRI was performed only in
BRCA carriers and one BC was detected only by this imag-
ing technique.
Eight DCIS were detected in women aged less than 50
years and 8 in women older than or equal to 50 years. The
screening sensitivity increased with age with a low rate in
the age group <50 (65%) and a very high rate (93%) in the
oldest age group, with an overall sensitivity of 82%.
The detection rates of BC were 31.6 per 1000 person-years
in BRCA1/2 gene mutation carriers, 6.9 per 1000 in the
high risk-group, 9.9 per 1000 person-years in the interme-
diate risk group, and 3.5 per 1000 in the slightly increased
risk-group. The incidence of BC in the entire study popu-
lation was significantly higher than expected (SIR = 4.9;
95% confidence interval (CI) = 1.6 to 7.6; p < 0.001). The
incidence was significantly higher among BRCA1 and
BRCA2 carriers (SIR = 20.3; 95% CI = 3.1 to 83.9; P <
0.001) and amongst subjects classified at high (SIR = 4.5;
95% CI = 1.5 to 8.3; P < 0.001) or intermediate risk (SIR
= 7.0, 95% CI = 2.0 to 17.1; P = 0.0018). However the inci-
dence of BC was not higher than expected in the group
classified at slightly increased risk (SIR = 2.4, 95% CI = 0.9
to 8.3; P = 0.74) (Table 6). Finally the SIR of BC was 14.4
(95% CI 6.7–26.5, P < 0.001) in the group of women aged
less than 50 years and 3.3 (95% CI 1.9–5.5 P < 0.001)
among women aged 50 years or older.
Discussion
Our clinical and radiological imaging surveillance pro-
gram led to the detection of 44 breast cancers, including
28 infiltrating and 16 in situ. The SIR for BC was very high
overall for the women in the study (4.9, P < 0.001) and
BRCA carriers (20.3, P < 0.001) compared to that expected
in the general age-matched population. In the high and
intermediate risk groups the SIR reached statistical signif-
icance (4.5, P < 0.001 and 7.0, P = 0.0018, respectively)
confirming the effectiveness of our current approach in
the identification of women at increased risk. On the
other hand, a low SIR (2.4, P = 0.76) was detected in the
slightly increased risk group. Interestingly, a much higher
proportion of DCIS (36%) was detected in our screening
compared with patients from an age-matched population
not considered at increased risk (9%). Furthermore, the
performance of our screening compares favourably with
the recommendations of the European Commission for
quality assurance in mammography screening [32] which
indicates a good detection rate in the first round where it
was more than 3.5 fold the incidence rate before screening
(2.6‰) and more than 1.5 fold in the subsequent rounds.
The combination of mammographic and ultrasound
screening in women with a family history was further
investigated. As in other studies, where ultrasound was
Actuarial five year survival rate Figure 1
Actuarial five year survival rate. Actuarial five year survival rate 
was 93%. After a median follow-up of 55 months four recur-
rences and three deaths were observed, two for disease pro-
gression and one for heart failure.
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useful for bridging the relatively long time interval
between the annual surveillance rounds [33,34], adding
ultrasound to mammography improved the sensitivity of
screening from 78% (28/36) to 97% (35/36). In all age
groups and risk categories, ultrasound showed a very high
sensitivity in addition to mammography with the excep-
tion of the slightly increased risk group where no cancer
was detected by this modality. As expected, the major
advantage of ultrasound was seen in women aged less
than 50 years where the sensitivity was up to 100% (from
7 to 11 of 11 cancers). Finally, although performed in a
limited number of cases, breast MRI screening showed
high sensitivity in women with a genetic predisposition
for BC. In fact, an interval cancer in a BRCA carrier patient,
had already appeared on an MRI, but was considered an
intramammary lymph node. A retrospective evaluation of
the preceding mammograms was performed for all inter-
val cancers, with the exception of one 32 year old woman
(Table 4) in the slightly increased risk group who had
never had a mammography before diagnosis. An interval
cancer in a 51 year old woman at high risk was considered
a missed cancer because the previous mammogram iden-
tified a mammary sprain at the left upper outer quadrant,
although a fine needle aspiration was negative for atypical
cells (Table 4). Also a DCIS in a 45 year old woman at
intermediate risk must be considered a missed cancer,
Table 5: Diagnostic sensitivities for the different imaging modalities for the 36 screen-detected BC
Mx US Mx+US MRI*
Sensitivity** Sensitivity** Sensitivity** Sensitivity**
(%) TP/TP+FN (%) TP/TP+FN (%) TP/TP+FN (%) TP/TP+FN
All women 78 28/36 50 18/36 97 35/36 100 4/4
< 50 years 64 7/11 64 7/11 100 11/11
≥ 50 years 84 21/25 44 11/25 96 24/25 100 4/4
BRCA+ 50 2/4 75 3/4 75 3/4 100 4/4
High risk 90 19/21 52 11/21 100 21/21
Intermediate risk 50 4/8 50 4/8 100 8/8
Slightly increased risk 100 3/3 0 0/3 100 3/3
Note.-  Mx = Mammography; US = Ultrasonography; MRI = Magnetic resonance imaging
* MRI was performed only in women who were BRCA carriers
** Sensitivity was defined as the percentage of cancers detected (with a specific modality) among all cancers detected with any modality: TP/
(TP+FN) where TP is true-positive and FN is false-negative
Table 4: Characteristics of patients with interval cancer
Age 
(years)
Risk group Detection 
method
Time from the 
last negative 
exam (months)
Type of 
tumor
Tumor 
size (cm)
Stage Grading Hormonal 
receptors 
ER/PgR (%)
Ki67 (%)
49 Intermediate CBE 10 Inflammatory 4* IV 3 0/0 nd
64 Slightly increased CBE 1 DCI 0.2° II 3 90/90 10
51 High CBE 9§ LCI 1.5 I 3 80/80 20
45 Intermediate CBE 14 DCIS∞ 0.6 is 1 0/0 nd
32• Slightly increased CBE+US 10 LCI 2 III 3 80/30 20
47 BRCA+ CBE+US 3® DCI 1.2 I 3 0/0 60
45 High CBE+US© 5 DCI 0.7 I 3 70/80 60
46 Intermediate CBE+US+Mx© 10 DCI 1.6 II 3 0/0 10
* The tumor size was determined at the time of mastectomy, after 8 cycles of preoperative chemotherapy
° Patient was diagnosed with axillary node involvement in the absence of radiological mammary signs; at the left upper outer quadrantectomy, a 0.2 
cm focus of DCI was evidenced
§Nine months prior to diagnosis, a fine needle aspiration of microcalcification clusters was negative for atypical cells
∞ Eleven months prior to diagnosis, a nipple discharge cytology was negative for atypical cells. Then she spontaneously contacted a surgeon who 
performed a subareolar biopsy that showed multiple foci of DCIS. She subsequently underwent mastectomy.
• No mammography was done before the diagnosis in consideration of the slightly increased risk and the young age of the patient
®Three months prior to diagnosis, an MRI showed a 9 mm lump in the lower left outer quadrant, with a fast wash in and wash out which was 
diagnosed as an intramammary lymph node.
© All preceding mammograms were retrospectively evaluated and were negative for suspicious signs. 
Note.nd -not determined ;ER – estrogen receptor; PgR – progesterone receptor; DCI -ductal carcinoma infiltrating ; LCI – lobular carcinoma 
infiltrating; DCIS – ductal carcinoma in situBMC Cancer 2006, 6:210 http://www.biomedcentral.com/1471-2407/6/210
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since the patient had a nipple discharge that was negative
for atypical cells. Excluding these cases, the real detection
rate of interval cancer was 0.8 per 1,000. All the invasive
interval cancers, except for 1 DCIS, had a tumor grading of
3. Nevertheless, the 5 years disease-free survival and over-
all survival for interval cancers was 100%, suggesting the
high compliance of women followed at our institution.
The overall percentage of tumors with positive lymph
nodes was 36% (10 of 28) with no difference in age or risk
group. The mean number of lymph nodes removed was
24. Other studies have reported a lower 10 – 35% node
positivity. The higher rate in our study may be due to dif-
ferent patient population characteristics, such as age or
screening schemes and modalities, or to our more strin-
gent node sampling.
The Saetersdal study [35] reported a detection rate of 15
per 1,000 on 537 women at risk for BC, who were selected
on the basis of autosomal dominant inheritance with
DCIS accounting for 11% of all cancers. Kollias [36] per-
formed a screening on 1371 women less than 50 years old
with a family history of BC; 23 invasive cancers were
detected during a mean follow-up of 22 months. The inci-
dence for invasive breast cancer was 7.9 per 1000 women-
years, with a SIR of 5 when compared with an age-
matched female population in the U.K. Six carcinomas in
situ (21%) were detected, suggesting that young women at
risk of BC due to family history may benefit from regular
breast screening for the early detection of in situ lesions.
Lalloo [37] selected 1259 women under the age of 50 with
a positive family history and a lifetime risk of BC of 1 in 6
or greater. In this population, 12 cancers were detected
giving a SIR of 1.42, 95% CI 0.73–2.48. The percent of
node-positive tumors (45%) was very high. Chart [38]
identified 24 tumors (invasive and in situ) in 1044
women distributed in three categories (high, moderate,
and slightly increased risk). All screen-detected tumors
were in situ or stage I, suggesting that surveillance of
women at increased risk for breast cancer may be useful in
detecting disease at an early stage. Finally, Brekelmans
[39], who has enrolled 1198 women characterized by
BRCA1/2 mutations or by a BC risk over 15% between
21–70 years of age in a screening program, found 35 can-
cers (31 invasive and 4 DCIS) after a median follow-up of
3 years. The SIR for invasive cancers was 7. Furthermore he
had a 74% screening sensitivity.
Both the Kollias and Lalloo studies analyzed young
women aged less than 50 years. In our study, 897 women
were under 50 years of age and 306 were older. The SIR of
BC in women aged <50 years was higher than that
observed in the U.K. screening program (14.4 vs.5), while
this ratio decreased in women aged more than 50 years.
The significance of detecting DCIS in mass screening pro-
grams is unknown. It is estimated that the risk of invasive
cancer following untreated DCIS in the general popula-
tion is 30–50% and this usually occurs within 10 years. In
the context of a family history, several investigators
believe detection of these non-invasive lesions may
become more important. The meaning of lobular carci-
noma in situ (LCIS) is debatable. This lesion was recently
considered as a high risk premalignant lesion such as
atypical ductal hyperplasia, papillomatosis, and so on
[40].
In conclusion the detection rate and the observed versus
expected ratio found in our surveillance program were in
accordance with the risk group, with a statistically signifi-
cant value for BRCA carriers, and for the high and interme-
diate risk groups. Also, the screening sensitivity was
improved in the above groups, but fell in the slightly
increased risk group. In this latter group, no significant
differences in detection rates and SIR were found with
respect to the expected number of BCs based on age-spe-
cific Modena Cancer Registry (MCR) rates from 1998
through 2002. As already reported by other authors [41],
early breast cancer screening does not seem to be cost-
effective in women belonging to a slightly increased risk
group. Newer imaging technologies, such as MRI, may
offer a better technique for the early diagnosis of breast
cancer, especially in BRCA1/2 gene carriers. Furthermore,
with the objective of reducing the number of interval can-
cers, randomized trials should be designed utilizing MRI
in the high and intermediate risk groups, as already pro-
posed by other authors [23,33].
Table 6: Observed and Expected Numbers of Breast Cancer per Risk Group
Risk group N° of women Observed n° of 
breast cancer
N°of person-
years at risk
Detection rate per 
1000 (95%CI)
Expected N° of 
breast cancer§
Ratio of Observed 
to Expected (SIR)®
p
BRCA1/2 48 5 158 31.6 (3.7–53.5) 0.13 2320.3(3.1–83.9) <0.001
High 674 23 3356 6.9 (1.9–10.6) 5.18 3 4.5 (1.5–8.3) <0.001
Intermediate 257 11 1108 9.9 (1.3–13.5) 1.23 7.0 (2.0–17.1) 0.0018
Slightly increased 346 5 1444 3.5 (0.1–6.0) 1.17 2.4 (0.9–8.3) 0.76
Overall 1325 44 6066 7.3 (2.2–11.1) 9.03 4.9 (1.6–7.6) <0.001
§For age-matched population according to Modena Cancer Registry 1998-2002.
®• SIR = Standard Incidence RatioBMC Cancer 2006, 6:210 http://www.biomedcentral.com/1471-2407/6/210
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Finally, our operational criteria seemed effective in identi-
fying people at increased risk of developing breast cancer,
and are currently being evaluated in a larger group of indi-
viduals from families followed at Institutions of the Ital-
ian Network on Hereditary Breast and Ovarian Cancer.
Conclusion
In conclusion, our data show that the proposed screening
program was able to select individuals at risk, in agree-
ment with the Italian Network on Hereditary Breast and
Ovarian Cancer. This paper provides evidence based proof
that an appropriate surveillance program can identify a
relevant number of breast cancers at an early stage in a
population at risk.
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